• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Enhancing Treatment Outcomes in Atrial Fibrillation: A Contemporary Literature Review of the Impact of Optimizing Patient Well-Being in Treatment Management.改善心房颤动的治疗效果:关于在治疗管理中优化患者健康状况影响的当代文献综述
Cureus. 2024 Jun 13;16(6):e62321. doi: 10.7759/cureus.62321. eCollection 2024 Jun.
2
Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry).欧洲心脏病专家对心房颤动患者的预后和治疗:EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase(EORP-AF Pilot 注册研究)的一年随访结果。
Eur Heart J. 2014 Dec 14;35(47):3365-76. doi: 10.1093/eurheartj/ehu374. Epub 2014 Aug 31.
3
Ablation of Atrial Fibrillation: Patient Selection, Periprocedural Anticoagulation, Techniques, and Preventive Measures After Ablation.心房颤动消融:患者选择、围手术期抗凝、技术及消融后预防措施
Circulation. 2016 Jul 26;134(4):339-52. doi: 10.1161/CIRCULATIONAHA.116.021727.
4
Evaluation of practice patterns in the treatment of atrial fibrillation among the commercially insured.商业保险人群中房颤治疗实践模式的评估。
Curr Med Res Opin. 2014 Sep;30(9):1707-13. doi: 10.1185/03007995.2014.922061. Epub 2014 Jun 2.
5
Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: atrial fibrillation type determines the success rate.肥厚型心肌病患者心房颤动的导管消融:心房颤动类型决定成功率。
Kardiol Pol. 2013;71(1):17-24.
6
Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass index categories: design and rationale for a retrospective cohort study.不同体重指数类别住院房颤患者直接口服抗凝剂的使用:一项回顾性队列研究的设计与原理
Ther Adv Drug Saf. 2024 Jan 27;15:20420986241227014. doi: 10.1177/20420986241227014. eCollection 2024.
7
Advanced electrophysiologic mapping systems: an evidence-based analysis.先进的电生理标测系统:基于证据的分析
Ont Health Technol Assess Ser. 2006;6(8):1-101. Epub 2006 Mar 1.
8
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry.在欧洲,阵发性与非阵发性心房颤动患者的“真实世界”管理和结局:EURObservational Research Programme - Atrial Fibrillation(EORP-AF)一般试点登记研究。
Europace. 2016 May;18(5):648-57. doi: 10.1093/europace/euv390. Epub 2016 Jan 29.
9
Management of atrial fibrillation: two decades of progress - a scientific statement from the European Cardiac Arrhythmia Society.心房颤动的管理:二十年的进展——欧洲心律失常学会的科学声明。
J Interv Card Electrophysiol. 2022 Oct;65(1):287-326. doi: 10.1007/s10840-022-01195-z. Epub 2022 Apr 13.
10
Ablation for atrial fibrillation: an evidence-based analysis.心房颤动的消融治疗:基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(7):1-63. Epub 2006 Mar 1.

本文引用的文献

1
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2023 ACC/AHA/ACCP/HRS 指南:心房颤动的诊断与管理——美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.
2
Alcohol consumption and atrial fibrillation risk: An updated dose-response meta-analysis of over 10 million participants.饮酒与房颤风险:对超过1000万参与者的最新剂量反应荟萃分析。
Front Cardiovasc Med. 2022 Sep 30;9:979982. doi: 10.3389/fcvm.2022.979982. eCollection 2022.
3
The WATCHMAN device and post-implantation anticoagulation management. A review of key studies and the risk of device-related thrombosis.WATCHMAN装置与植入后抗凝管理。关键研究及与装置相关血栓形成风险的综述。
Am J Cardiovasc Dis. 2021 Dec 15;11(6):714-722. eCollection 2021.
4
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry.新型口服抗凝药和维生素 K 拮抗剂在新发心房颤动中的出血及相关死亡率:来自 GARFIELD-AF 注册登记研究的结果。
Blood Adv. 2021 Feb 23;5(4):1081-1091. doi: 10.1182/bloodadvances.2020003560.
5
Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association.生活方式和危险因素的改变以减少心房颤动:美国心脏协会的科学声明。
Circulation. 2020 Apr 21;141(16):e750-e772. doi: 10.1161/CIR.0000000000000748. Epub 2020 Mar 9.
6
Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review.阻塞性睡眠呼吸暂停与心房颤动及持续气道正压通气治疗的相关性:综述。
JAMA Cardiol. 2018 Jun 1;3(6):532-540. doi: 10.1001/jamacardio.2018.0095.
7
Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss and Exercise.肥胖与心房颤动的患病率、发病机制和预后:体重减轻和运动的影响。
J Am Coll Cardiol. 2017 Oct 17;70(16):2022-2035. doi: 10.1016/j.jacc.2017.09.002.
8
Connexin Remodeling Contributes to Atrial Fibrillation.连接蛋白重塑与心房颤动有关。
J Atr Fibrillation. 2013 Aug 31;6(2):839. doi: 10.4022/jafib.839. eCollection 2013 Aug-Sep.
9
Alcohol and Atrial Fibrillation: A Sobering Review.酒精与心房颤动:冷静反思。
J Am Coll Cardiol. 2016 Dec 13;68(23):2567-2576. doi: 10.1016/j.jacc.2016.08.074.
10
Impact of obesity and weight loss on cardiac performance and morphology in adults.肥胖和减肥对成年人心脏功能和形态的影响。
Prog Cardiovasc Dis. 2014 Jan-Feb;56(4):391-400. doi: 10.1016/j.pcad.2013.09.003. Epub 2013 Oct 26.

改善心房颤动的治疗效果:关于在治疗管理中优化患者健康状况影响的当代文献综述

Enhancing Treatment Outcomes in Atrial Fibrillation: A Contemporary Literature Review of the Impact of Optimizing Patient Well-Being in Treatment Management.

作者信息

Obi Mukosolu F, Sharma Manjari, Namireddy Vikhyath, Patel Vyoma, Reinberg Palmar Arianna, Kanu Ngozi T

机构信息

Internal Medicine, Wyckoff Heights Medical Center, Brooklyn, USA.

Medicine, St. George's University School of Medicine, True Blue, GRD.

出版信息

Cureus. 2024 Jun 13;16(6):e62321. doi: 10.7759/cureus.62321. eCollection 2024 Jun.

DOI:10.7759/cureus.62321
PMID:39006593
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11246104/
Abstract

Atrial fibrillation (AF) is the most common heart rhythm disorder, defined by an irregular and rapid heartbeat. It is the most prevalent cardiac arrhythmia in the United States, characterized by irregular heartbeats due to asynchrony between atrial and ventricular contractions. AF can be categorized as paroxysmal or persistent and, as such, poses significant health risks, including heart failure and stroke. Factors like age, sex, lifestyle, and existing health conditions elevate AF risk. There have been a lot of debates around AF risk management and its impact on prognosis. This literature review aims to explore the influence of addressing modifiable risk factors in AF patients on its morbidity and mortality, exploring various treatment options and their effectiveness. Current guidelines suggest rate control and anticoagulation for persistent AF with medications like beta blockers and non-vitamin K oral anticoagulants. Catheter ablation for rhythm control is contentious. Studies on supplemental treatments, lifestyle changes, and managing comorbidities show mixed results, necessitating further research for comprehensive treatment effectiveness in AF patients, which this literature review will discuss.

摘要

心房颤动(AF)是最常见的心律紊乱,其定义为心跳不规则且快速。它是美国最普遍的心律失常,其特征是由于心房和心室收缩不同步导致心跳不规则。AF可分为阵发性或持续性,因此会带来重大健康风险,包括心力衰竭和中风。年龄、性别、生活方式和现有健康状况等因素会增加AF风险。围绕AF风险管理及其对预后的影响存在很多争论。这篇文献综述旨在探讨针对AF患者可改变的风险因素对其发病率和死亡率的影响,探索各种治疗选择及其有效性。当前指南建议使用β受体阻滞剂和非维生素K口服抗凝剂等药物对持续性AF进行心率控制和抗凝治疗。用于节律控制的导管消融存在争议。关于补充治疗、生活方式改变和合并症管理的研究结果不一,因此需要进一步研究AF患者综合治疗的有效性,本文献综述将对此进行讨论。